ACT heads into its August 28 earnings release with the founder-CEO quietly adding to his position, borrow costs running well above average, and a stock that has gained 18% in a month but slipped modestly on the week.
The clearest immediate story is insider conviction. CEO and founder Ofer Vicus bought shares twice in the past three months — 2,500 shares in mid-May and another 2,360 on June 23 — at prices near CAD 20-21. An independent director, Peter Kampian, added 5,000 shares on the same June date. Net insider buying over the 90-day window totals roughly 9,860 shares, with a combined value of approximately CAD 146,000. These are small absolute amounts for a micro-cap, but the clustering of purchases from the founder and a board member, both at prices close to current levels, reflects a degree of confidence ahead of the upcoming print.
The lending market tells a tighter story than the headline short interest figure suggests. Short interest is genuinely low — just 0.16% of the free float — so there is no meaningful bear conviction in the positioning. The borrow cost is a different matter entirely. At 16.5%, cost-to-borrow has been running persistently elevated for months, easing only slightly from a peak near 19% in mid-August. More telling is the availability picture: only about 27% of borrowed shares remain available in the lending pool, down sharply from 33% at the start of the week, and well above the 52-week floor of 0.44% — a level that was touched in mid-July when availability compressed to near zero. That July episode, when utilization hit 92.8% and borrow availability briefly collapsed to under 10%, stands as a reminder of how quickly the lending market can tighten on this illiquid name. Current conditions are looser than that, but the direction of travel this week is tightening.
The ORTEX short score has been remarkably stable, hovering in a narrow band around 51.9 for the past two weeks — a middling reading that reflects the tension between strong recent momentum and weak fundamental underpinnings. The company's sector score has improved materially, and the 50-day moving average now runs roughly 15% above the 200-day. But quality metrics remain a headwind: the Piotroski F-score is just 2, return on assets is deeply negative, and there are no positive earnings or cash flow yields to anchor valuation. The EV data on file is stale and not directly usable as a current valuation anchor. There are no analyst ratings on record. The stock is essentially trading on momentum and narrative rather than fundamental multiples.
Peers tracked by correlation correlation — SSYS, DDD, UAVS — all fell sharply on the week, with UAVS down 14% and DDD off nearly 10%. ACT's relative resilience, losing less than 1% on the week despite that peer pressure, is worth noting for a stock with no analyst coverage and thin institutional ownership. The largest registered holder, Vicus himself, holds 27.6% of shares outstanding. The next ten institutional holders collectively represent less than 2% of the float.
What to watch at the August 28 print: past releases have produced asymmetric five-day outcomes — a 17% five-day gain after April's results, and a near-10% five-day loss after January's — suggesting the stock moves hard in either direction once a catalyst arrives, even when the one-day reaction is muted.
See the live data behind this article on ORTEX.
Open ACT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
